Buying guide
Lingo vs Pixel Watch in 2026
Comparing 2 humanoid robots across availability, pricing, capabilities, and verified deployments. Current as of 2026.
| Attribute | No image on file | |
|---|---|---|
| Manufacturer | Abbott | |
| Form factor | biometric | biometric |
| Maturity | commercial | commercial |
| Availability | shipping-nowshipping | shipping-nowshipping |
| Price | $54 (actual sale price) | $349-$399 (actual sale price) |
| Capability claims | — |
|
| Brain | — | — |
| Verified deployments | 1Abbott | 0 |
| Privacy practices | 4third-party-sharing, data-deletion-control, biometric-storage, training-data-use | 11cloud-upload, data-deletion-control, data-sale, data-retention, location-tracking, third-party-sharing, biometric-storage, biometric-storage, data-sale, data-deletion-control, data-retention |
| Sources on file | 8 | 17 |
Editorial summaries
Lingo
Abbott's Lingo is an over-the-counter continuous glucose monitor for non-diabetic and wellness consumers, built on Abbott's FreeStyle Libre sensor platform (FDA 510(k) K233655, decided May 29, 2024; Class II integrated CGM): a disposable biosensor worn up to 14 days on the back of the upper arm. It is the adaptive-algorithmic end of the glucose cell, the documented contrast to Stelo's generative AI: the app's 'Lingo Count' daily glucose-spike metric with adaptive targets, food and activity logging, and rule-based personalized recommendations are adaptive-algorithmic, not generative. 'Lingo Live' is free roughly 30-minute sessions with human Abbott nutritionists, not an AI coach, and DEPLOY surfaces that distinction prominently. Pricing starts at about $54 for a 2-week single-biosensor plan, with recurring biweekly and monthly multi-sensor tiers. From Abbott (NYSE: ABT). Cap-flag: the cleared indication is adults 18+ not on insulin, explicitly NOT for diagnosis of any disease including diabetes.
Pixel Watch
The Google Pixel Watch (current hardware the Pixel Watch 4, October 2025; the Pixel Watch 3 remains supported) is a biometric-primary smartwatch and the first-of-kind-cleared archetype of the cohort. Its sensors (multipath PPG heart rate, ECG via crown and caseback, SpO2, skin temperature, accelerometer) drive HRV, breathing rate, and resting heart rate, on Fitbit and Google Health algorithms (Google owns Fitbit). It is a hardware purchase (about $349 for the 41mm aluminum, $399 for the 45mm, plus about $100 for LTE), with an optional Google Health Premium subscription ($9.99/month) that gates the Sleep Profile and the Gemini AI coach. DEPLOY records commercial maturity. Its standout verified achievement is loss-of-pulse detection, which received an FDA De Novo authorization in February 2025, a first-of-kind clearance for cardiac-event detection on a consumer watch; the cleared indication is specific and should not be read as a general cardiac-diagnostic claim. Google's broader biometric strategy also spans Fitbit (Charge, Sense, Versa).
Machine-readable: this page as markdown.